Sangamo Therapeutics Faces Deplorable Stock Plunge Following Pfizer's Withdrawal from Hemophilia Treatment Deal

Sangamo Therapeutics, a company specializing in gene therapy and related innovations, witnessed a catastrophic decline in its stock value after pharmaceutical giant Pfizer decided to terminate their partnership regarding a hemophilia treatment. This abrupt end to the collaboration has sent shockwaves through the markets and raised numerous questions about the future capabilities and financial health of Sangamo.

Continue reading